Yunfei Wang

发表

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

J. O’Shaughnessy, J. Goldschmidt, J. Blum, 2019, npj Breast Cancer.

Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.

E. Nadler, S. Ogale, Anupama Vasudevan, 2022, Cancer treatment and research communications.

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.

K. Kolibaba, R. Taetle, S. Vukelja, 2008, Blood.

Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study

E. Liu, S. Paulson, Yunfei Wang, 2022, Oncology and Therapy.

Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.

S. Papish, P. Fox, F. Holmes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients

J. O’Shaughnessy, S. Vukelja, J. W. Smith, 2013, Breast Cancer Research and Treatment.

A prospective Phase III trial evaluating patient self‐reported pain and cosmesis in accelerated partial breast irradiation utilizing 3‐D versus intensity‐modulated radiotherapy

L. Barke, T. Kaske, L. Asmar, 2021, Cancer medicine.

Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer

G. Lyman, P. Fox, D. Patt, 2018, Clinical breast cancer.

Retrospective Study of Real-World Treatment Patterns and Outcomes in Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Lenvatinib/Everolimus after Heavy Pretreatment1

N. Robert, N. Vogelzang, N. Tannir, 2021, Kidney Cancer.

Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting.

N. Robert, N. Vogelzang, N. Tannir, 2021, Clinical genitourinary cancer.

Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC).

G. Sonpavde, M. Galsky, B. Hellerstedt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes After Accelerated Partial Breast Irradiation in Women With Triple Negative Subtype and Other “High Risk” Variables Categorized as Cautionary in The ASTRO Guidelines

L. Barke, L. Asmar, C. Leonard, 2021, Frontiers in Oncology.

Analysis of the Expression and Clinical Significance of VIPR1 in Lung Adenocarcinoma Based on TCGA Database

Huaqi Wang, Xiaobo Li, Guojun Zhang, 2021 .

Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer

J. O’Shaughnessy, L. Asmar, John W. Smith, 2009, Breast Cancer Research and Treatment.

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

T. Powles, G. Sonpavde, M. Galsky, 2013, Clinical genitourinary cancer.

Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer

C. Obasaju, M. Socinski, D. Patt, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.

G. Lyman, D. Patt, L. Asmar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

N. Robert, F. Holmes, J. O’Shaughnessy, 2013, The Lancet. Oncology.

Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma

K. Kolibaba, P. Flynn, L. Garbo, 2009, Investigational New Drugs.

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

J. O’Shaughnessy, J. Goldschmidt, J. Blum, 2019, npj Breast Cancer.

PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.

J. O’Shaughnessy, J. Blum, S. Vukelja, 2011 .

Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer

F. Holmes, J. O’Shaughnessy, B. Hellerstedt, 2018, Cancer medicine.

Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.

G. Sonpavde, M. Galsky, D. Martincic, 2012, Clinical genitourinary cancer.

Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC).

G. Sonpavde, M. Galsky, B. Hellerstedt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2‐neu Negative and Triple Negative Metastatic Breast Cancer

F. Holmes, J. O’Shaughnessy, M. Neubauer, 2017, Clinical breast cancer.

Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

M. Danso, J. O’Shaughnessy, Ling Ma, 2021, JAMA network open.

Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.

J. O’Shaughnessy, S. Peck, A. Melnyk, 2019, The oncologist.

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer

J. Rassen, S. Schneeweiss, N. Robert, 2023, Targeted Oncology.

Preliminary Toxicity Results of a Phase II Randomized Trial of Weekly or Every 3-Week Ixabepilone in Metastatic Breast Cancer (MBC).

J. O’Shaughnessy, S. Vukelja, L. Asmar, 2009 .

Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology setting

B. Seal, A. Aly, A. He, 2023, Hepatic oncology.

Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer

Simin Hu, S. Vukelja, D. Richards, 2011, Investigational New Drugs.